过去一年中添加的文章，按日期排序
Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systemic review and network meta-analysis
S Ren, Y Zhao, J Wu, S Ren, Y Feng - Frontiers in Pharmacology - frontiersin.org
14 天前 - … Methods A systematic search was conducted in the … safety of HIF-PHIs for anemia
in CKD were included. The efficacy outcome included change of hemoglobin and the safety …
in CKD were included. The efficacy outcome included change of hemoglobin and the safety …
[HTML][HTML] SHIFTING PARADIGMS: EXPLORING ENARODUSTAT FOR ANEMIA IN CHRONIC KIDNEY DISEASE IN A META ANALYSIS OF RANDOMIZED …
LH Tanrıverdi, A Sarıcı - Hematology, Transfusion and Cell Therapy, 2024 - Elsevier
68 天前 - … Additionally, hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors have …
the efficacy, safety, and tolerability of enarodustat in anemic CKD patients. Case report …
the efficacy, safety, and tolerability of enarodustat in anemic CKD patients. Case report …
Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia
T Nakanishi, T Kuragano - Clinical Kidney Journal, 2024 - academic.oup.com
130 天前 - … Therefore, the potential inhibition of AKG-associated metabolic systems by HIF-PHIs …
In particular, we would posit that it may be safe to withhold HIFPHIs from patients with …
In particular, we would posit that it may be safe to withhold HIFPHIs from patients with …
[HTML][HTML] Quantitative systems pharmacology model of erythropoiesis to simulate therapies targeting anemia due to chronic kidney disease
M Roy, S Saroha, U Sarma, H Sarathy… - Frontiers in …, 2023 - frontiersin.org
262 天前 - … However, due to safety risks associated with … Prolyl hydroxylase inhibitors are a
class of orally administered, … Preventing HIF-α prolyl hydroxylation inhibits HIF-α degradation. …
class of orally administered, … Preventing HIF-α prolyl hydroxylation inhibits HIF-α degradation. …
[HTML][HTML] … -prolyl hydroxylase inhibitors vs. erythropoietin-stimulating agents in treating anemia in renal patients (with or without dialysis): a meta-analysis and systematic …
N Damarlapally, V Thimmappa, H Irfan, M Sikandari… - Cureus, 2023 - ncbi.nlm.nih.gov
270 天前 - … Therefore, in these patients, we propose HIF-PHI alongside renal anemia treatment.
… the safety and efficacy of HIF-PHIs compared to ESAs in treating anemia in CKD patients. …
… the safety and efficacy of HIF-PHIs compared to ESAs in treating anemia in CKD patients. …